Rexahn Pharmaceuticals, Inc.
) announced initial data from its ongoing phase I dose-escalation
study on Supinoxin (RX-5902). The drug was well tolerated in
cancer patients with solid tumors.
The study is evaluating the safety, tolerability and dose
limiting toxicities of Supinoxin as well as maximal tolerated
dose (MTD) in patients suffering from solid cancer tumors who
have failed prior treatment with other approved therapies and
whose disease has progressed.
Rexahn has completed three dosing cycles (25mg, 50mg and 100 mg)
in the ongoing study. So far, no adverse incidents related to the
dosing of Supinoxin have occurred and the fourth dosing cycle
with 150 mg of Supinoxin has been initiated. The MTD is yet to be
achieved. Initial data from the study showed that the
pharmacokinetic profile and oral bioavailability of Supinoxin was
similar to that observed in preclinical studies.
Meanwhile, Rexahn is advancing with its other oncology
candidates, Archexin and RX-3117. Archexin is in a phase IIa
proof-of-concept study in patients suffering from metastatic
renal cell carcinoma (RCC). Additionally, RX-3117 is in a phase
Ib study in patients with solid tumors. The company expects to
complete enrolling patients for this study by the end of 2014.
Data readout is expected in the first half of 2015.
We expect investor focus to remain on pipeline updates from the
Rexahn carries a Zacks Rank #3 (Hold). Some better-ranked stocks
in the biotech sector include
Alexion Pharmaceuticals, Inc.
Gilead Sciences Inc.
). All these stocks carry a Zacks Rank #1 (Strong Buy).
ALEXION PHARMA (ALXN): Free Stock Analysis
AMGEN INC (AMGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis
REXAHN PHARMACT (RNN): Get Free Report
To read this article on Zacks.com click here.